Published On: Mon, Apr 24th, 2017

New Analyst Ratings On Imprimis Pharmaceuticals, Inc. (IMMY)


Recently stock market analysts have updated their consensus ratings on shares of Imprimis Pharmaceuticals, Inc. (IMMY).

Most recent broker ratings

03/22/2017 – Imprimis Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Rodman & Renshaw. They now have a USD 5 price target on the stock.

07/23/2015 – Sterne Agee began new coverage on Imprimis Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 10 price target on the stock.

03/10/2015 – Imprimis Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at Zacks. They now have a USD 8.4 price target on the stock.

12/18/2014 – CRT Capital began new coverage on Imprimis Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 13 price target on the stock.

12/16/2014 – Craig-Hallum began new coverage on Imprimis Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 12 price target on the stock.

Imprimis Pharmaceuticals, Inc. has a 50 day moving average of 3.27 and a 200 day moving average of 2.76. The stock’s market capitalization is 82.70M, it has a 52-week low of 1.65 and a 52-week high of 4.69.

The share price of the company (IMMY) was up +2.54% during the last trading session, with a high of 4.50 and the volume of Imprimis Pharmaceuticals, Inc. shares traded was 327233.